Plaintiff

Array BioPharma, Inc.

3 cases as plaintiff.

Cases
3
Active
0
3 closed
Filed
2022–2023
Top venue
D. Delaware
3 cases

Company profile

Array BioPharma, Inc. — commonly "Array" — is a biopharmaceutical company founded in 1998 and headquartered in Boulder, Colorado. It operated as a publicly traded company on the Nasdaq (ticker ARRY) until July 30, 2019, when Pfizer Inc. (NYSE: PFE) completed its acquisition of Array for $48 per share, roughly $11.4 billion in enterprise value. Array is now a wholly owned Pfizer subsidiary, with its Boulder site folded into Pfizer's Oncology R&D network alongside Cambridge, Massachusetts and Morrisville, North Carolina. Array common stock ceased trading on the Nasdaq Global Market at closing; no current standalone employee count or revenue exists since Pfizer does not report Array separately.

Products / operations. Array is a commercial-stage, fully integrated oncology company focused on targeted small-molecule drugs. Its marketed products are BRAFTOVI (encorafenib) capsules and MEKTOVI (binimetinib) tablets, approved in combination in the U.S. for unresectable or metastatic melanoma with BRAF V600E/V600K mutations, and later developed toward BRAF-mutant metastatic colorectal cancer (BEACON CRC trial). Former clinical programs include selumetinib and binimetinib partnerships, with ex-U.S. commercialization rights licensed to Pierre Fabre and Japan/Korea rights to Ono Pharmaceutical.

Patent-litigation posture. Array is an operating company asserting product patents, not a non-practicing entity. The tracked data show 3 cases as plaintiff and 0 as defendant, all in the U.S. District Court for the District of Delaware — a standard venue for Hatch-Waxman ANDA litigation, not a plaintiff-friendly NPE venue. All three suits target generic-drug manufacturers seeking to market versions of Array's approved products.

Notable cases. The tracked suits are Array BioPharma, Inc. v. Teva Pharmaceuticals, Inc. (filed 2023-06-08), Array BioPharma, Inc. v. Sandoz Inc. (2022-10-06), and Array BioPharma, Inc. v. Alembic Pharmaceuticals Limited et al. (2022-09-28). All are patent-enforcement actions tied to Array's BRAFTOVI/MEKTOVI franchise, which is protected by numerous listed U.S. patents with expirations extending into the early 2030s. No merits outcome is asserted here.

Sources: Pfizer press releases (2019 acquisition); Array investor materials; Denver Post/Denver Business Journal coverage; DrugPatentWatch listings.

Watchlist

Get alerted when Array BioPharma, Inc. sues again.

Email-only, free, anonymous. We'll notify you when Array BioPharma, Inc. files another patent-infringement lawsuit. One-click unsubscribe from any alert.

Filing activity

2022: 2 cases2'222023: 1 case'23
Cases filed per year with Array BioPharma, Inc. as plaintiff.

Array BioPharma, Inc. v. Teva Pharmaceuticals, Inc.

settled
Docket:
1:23-cv-00625-GBW
Filed:
2023-06-08
Terminated:
2025-08-01
Patents:9314464956201695983769980944
π Array BioPharma, Inc.Δ Teva Pharmaceuticals, Inc.

Hatch-Waxman ANDA litigation brought by Array BioPharma against Teva over Teva's generic binimetinib 15 mg tablets (ANDA No. 217509). The case ended in a stipulated dismissal/settlement after briefing on Teva's stay motion pending appeal of the crystallized binimetinib claim construction from the Alembic/Sandoz litigation. Although U.S. 9,314,464 appeared on the case's USPTO report, the narrative states Array asserted only the three Crystallized Binimetinib Patents (U.S. 9,562,016; 9,598,376; 9,980,944) against Teva, and Teva's Paragraph IV notice did not address the '464 patent.

Array BioPharma, Inc. v. Sandoz Inc.

settled
Docket:
1:22-cv-01316-GBW
Filed:
2022-10-06
Terminated:
2025-01-09
Patents:9314464985022910005761956201695983769980944
π Array BioPharma, Inc.Δ Sandoz Inc.

Hatch-Waxman ANDA litigation brought by Array BioPharma against Sandoz over generic binimetinib. The case ended in a stipulated dismissal without prejudice under a confidential settlement and license agreement, expressly not an adjudication on the merits; Sandoz could maintain its existing Paragraph IV certifications and FDA was not barred from final ANDA approval. The dismissal order recited '9,850,299'; the narrative states the corresponding family patent is U.S. 9,850,229.

Array BioPharma, Inc. v. Alembic Pharmaceuticals Limited et al.

settled
Docket:
1:22-cv-01277-GBW
Filed:
2022-09-28
Terminated:
2025-06-10
Patents:9314464985022910005761956201695983769980944
π Array BioPharma, Inc.Δ Alembic Pharmaceuticals LimitedΔ Alembic Pharmaceuticals, Inc.

Hatch-Waxman ANDA litigation brought by Array BioPharma against Alembic over generic binimetinib 15 mg tablets (ANDA No. 217678). The case was terminated by stipulated dismissal after a confidential settlement and license agreement, expressly not an adjudication on the merits, with no finding of infringement, invalidity, or unenforceability. A May 28, 2024 stipulated order addressed certain claims but did not become a final, appealable judgment.